Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Public ClinicalTrials.gov record NCT03409614. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Study identification
- NCT ID
- NCT03409614
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Enrollment
- 789 participants
Conditions and interventions
Conditions
Interventions
- Chemotherapy Other
- Placebo Drug
- REGN2810 Drug
- REGN2810/chemo/ipi Drug
Other · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 5, 2018
- Primary completion
- Feb 26, 2025
- Completion
- Feb 26, 2025
- Last update posted
- May 17, 2026
2018 – 2025
United States locations
- U.S. sites
- 9
- U.S. states
- 6
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Regeneron Research Site | Rancho Mirage | California | 92270 | — |
| Regeneron Research Site | Riverside | California | 92506 | — |
| Regeneron Research Site | Whittier | California | 90603 | — |
| Regeneron Research Site | Orange City | Florida | 32763 | — |
| Regeneron Research Site | St. Petersburg | Florida | 33709 | — |
| Regeneron Research Site | Wichita | Kansas | 67214 | — |
| Regeneron Research Site | Bethesda | Maryland | 20817 | — |
| Regeneron Research Site | Farmington | New Mexico | 87401 | — |
| Regeneron Research Site | Gettysburg | Pennsylvania | 17325 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 124 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03409614, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 17, 2026 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03409614 live on ClinicalTrials.gov.